The present invention describes a composition comprising a mixture of human foetal keratinocyte cells and human foetal fibroblast cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5, preferably being 1:1 or 7:3. This composition is advantageously included in a bandage, said bandage preferably being sterile and packaged in a container impermeable to microorganisms. The present invention finally concerns the use of this composition as a drug, in particular for treating a skin defect (wound, burn or ulcer).

The present invention describes a composition comprising a mixture of human foetal keratinocyte cells and human foetal fibroblast cells, the ratio between said keratinocyte and fibroblast cells ranging from 0.75 to 2.5, preferably being 1:1 or 7:3. This composition is advantageously included in a bandage, said bandage preferably being sterile and packaged in a container impermeable to microorganisms. The present invention finally concerns the use of this composition as a drug, in particular for treating a skin defect (wound, burn or ulcer).

Devices, and methods for preventing immune rejections are disclosed, in which trophoblasts or trophoblast-like cells are used to induce tolerance toward allogeneic cell and tissue grafts. The devices can be used as artificial placenta vaccines to avoid immunosuppression in organ transplantation.

Devices, and methods for preventing immune rejections are disclosed, in which trophoblasts or trophoblast-like cells are used to induce tolerance toward allogeneic cell and tissue grafts. The devices can be used as artificial placenta vaccines to avoid immunosuppression in organ transplantation.

The present invention provides dynamically covalent polymeric hydrogel systems for encapsulating and stabilizing bioactive therapeutic agents (e.g., proteins, cells, viruses, and vaccines) from environmental stressors, obviating standard refrigeration requirements, and decreasing transportation and storage costs of temperature-sensitive biomolecules. Described herein are dynamic polymeric hydrogel compositions comprising a therapeutic agent and a combination of phenylboronic acid- and 1,2-diol-modified multi-arm polyethylene glycol (PEG) polymer backbones. Methods of encapsulating and stabilizing bioactive therapeutic agents within the dynamic polymeric hydrogel compositions are also provided. Also described are methods for releasing stabilized therapeutic agents from hydrogel encapsulation. The covalently adaptable hydrogel release systems allow for discretionary administration of temperature-sensitive therapeutic agents, as well as the parenteral administration of highly concentrated amounts of therapeutic agents.

The present invention provides dynamically covalent polymeric hydrogel systems for encapsulating and stabilizing bioactive therapeutic agents (e.g., proteins, cells, viruses, and vaccines) from environmental stressors, obviating standard refrigeration requirements, and decreasing transportation and storage costs of temperature-sensitive biomolecules. Described herein are dynamic polymeric hydrogel compositions comprising a therapeutic agent and a combination of phenylboronic acid- and 1,2-diol-modified multi-arm polyethylene glycol (PEG) polymer backbones. Methods of encapsulating and stabilizing bioactive therapeutic agents within the dynamic polymeric hydrogel compositions are also provided. Also described are methods for releasing stabilized therapeutic agents from hydrogel encapsulation. The covalently adaptable hydrogel release systems allow for discretionary administration of temperature-sensitive therapeutic agents, as well as the parenteral administration of highly concentrated amounts of therapeutic agents.

The present disclosure provides methods for restoring reproductive health and/or fertility in a subject by delivering immature follicles to the subject using an ovarian-derived hydrogel. The present disclosure also provides methods for treating ovarian-associated diseases using ovarian-derived hydrogels or their derivatives for delivery of therapeutic agents to the subject in need thereof. The present disclosure further provides kits for restoring reproductive health and/or fertility, and kits for treating ovarian-associated diseases.

The present disclosure provides methods for restoring reproductive health and/or fertility in a subject by delivering immature follicles to the subject using an ovarian-derived hydrogel. The present disclosure also provides methods for treating ovarian-associated diseases using ovarian-derived hydrogels or their derivatives for delivery of therapeutic agents to the subject in need thereof. The present disclosure further provides kits for restoring reproductive health and/or fertility, and kits for treating ovarian-associated diseases.

The present disclosure provides methods for restoring reproductive health and/or fertility in a subject by delivering immature follicles to the subject using an ovarian-derived hydrogel. The present disclosure also provides methods for treating ovarian-associated diseases using ovarian-derived hydrogels or their derivatives for delivery of therapeutic agents to the subject in need thereof. The present disclosure further provides kits for restoring reproductive health and/or fertility, and kits for treating ovarian-associated diseases.

The present invention is drawn to novel methods of selecting mammals receptive to embryo transfers in order to improve reproductive efficiency and milk production of the mammals. The present invention encompasses three methods: (1) selecting from any group of mammals; (2) selecting from estrus-negative mammals; and (3) selecting from estrus-negative mammals and pooling the selected mammals with estrus-positive mammals. Also encompassed is a kit for selecting mammals receptive to embryo transfers.